Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ: OCGN )

0.6800 -0.0200 (-2.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
33 34 Next >
20 Stocks Moving in Monday's Pre-Market Session
Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) rose 85.6% to $3.88 in pre-market trading after jumping 14% on Friday. Petros Pharmaceuticals recently said Q3 sales results... 
Via Benzinga
56 Biggest Movers From Friday
Gainers iSpecimen Inc. (NASDAQ: ISPC) climbed 71.7% to settle at $17.51 on Friday. The company recently announced it has been contracted to support new advanced research on... 
Via Benzinga
48 Stocks Moving In Friday's Mid-Day Session
Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares jumped 68% to $9.04. Shares of mask and protective apparel companies, including Allied Healthcare Products, traded... 
Via Benzinga
OCGN Stock Alert: The FDA News Sending Ocugen Plummeting Today
Shares of OCGN stock are under pressure after the FDA halted the approval process of Covaxin, a major setback for Ocugen. 
Via InvestorPlace
Exposures Product Safety
Ocugen Shares Fall After Its Pivotal COVID-19 Vaccine Trial Put On FDA Hold
The FDA has issued a clinical hold on Ocugen Inc's (NASDAQ: OCGN) Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate,... 
Via Benzinga
Exposures COVID-19 Product Safety
25 Stocks Moving in Friday's Pre-Market Session
Gainers iSpecimen Inc. (NASDAQ: ISPC) rose 56.9% to $16.00 in pre-market trading. The company recently announced it has been contracted to support new advanced research on COVID-... 
Via Benzinga
3 Small-Cap COVID Stocks With Huge Upside
Three Fool.com contributors are bullish on Beyond Air, Ocugen, and Fulgent Genetics. 
Via The Motley Fool
Exposures COVID-19
Think Twice Before You Roll the Dice on Ocugen Stock
OCGN stock may spike once again on positive news, but investors' best best is to steer clear of it at this point in time. 
Via InvestorPlace
Exposures COVID-19
Ocugen-Partnered Bharat Biotech's COVID-19 Shot Shows 50% Effectiveness In Small Study In India
Bharat Biotech's vaccine was found to be 50% effective at preventing symptomatic COVID-19 in a high-risk population during the second wave of infections in India this year,... 
Via Benzinga
Exposures COVID-19
Better Buy: Ocugen or Novavax?
Will either of these hopeful vaccine makers continue to thrash the market? 
Via The Motley Fool
Exposures COVID-19
Battle of the COVID Vaccine Contenders: Inovio vs. Ocugen
Both vaccine makers still have big hurdles to jump. 
Via The Motley Fool
Exposures COVID-19
Ocugen Stock: Bull vs. Bear
There's more to this potential coronavirus vaccine stock than what happens in the next 12 months. 
Via The Motley Fool
Exposures COVID-19
Why Ocugen Shot 8% Higher on Friday
There was some highly encouraging news about coronavirus vaccines, but not the one the company is associated with. 
Via The Motley Fool
Exposures COVID-19
The Slide in Ocugen Could Be a Slide to a Homerun
Ocugen has potential for its gene therapy treatment for eye diseases, but OCGN stock movement has been all about Covaxin. 
Via InvestorPlace
Why This Meme Stock Isn't Worth the Trouble
This biotech is targeting a lucrative market, but it may be too late for the company. 
Via The Motley Fool
3 Biotech Stocks That Have More Than Tripled so far This Year
But can they keep up the momentum? 
Via The Motley Fool
2 More Stocks Set to 2x… 5x… 10x in 2022
Finding 10x stocks is possible; it's simply a matter of knowing what patterns to look for. Here are a couple of strong contenders. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
3 Things About Ocugen That Smart Investors Know
Revenue may not be right around the corner. 
Via The Motley Fool
Exposures COVID-19
Ocugen Proves Groupthink Is a Double-Edged Sword
While OCGN stock is an intriguing idea on the science, when the masses have a different framework, it becomes a risky proposition. 
Via InvestorPlace
Ocugen Needs More Than Covaxin to Boost Its Falling Shares
A doomed-looking vaccine partnership puts Ocugen back in the business of obscurity and OCGN stock at risk of much lower prices. 
Via InvestorPlace
As OCGN Stock Trudges Along Without Real Hope Must Wane
Ocugen is nothing but false hope despite positive news 
Via InvestorPlace
Here's What Needs to Happen for Ocugen Stock to Be a Screaming Buy
The company needs clear regulatory wins in the U.S. and Canada. 
Via The Motley Fool
Is Ocugen About to Beat Moderna in This One Market?
Ocugen aims to be among the first to carve out market share. 
Via The Motley Fool
Exposures COVID-19
WHO’s Nod Can’t Mask Ocugen’s Flimsy Fundamentals
Ocugen has been trying to commercialize a Covid-19 vaccine. However, it's facing many obstacles. Meanwhile, insiders are dumping OCGN stock. 
Via InvestorPlace
Exposures COVID-19
7 Stocks To Sell Before They Head to The Market Graveyard
So, which ones are stocks to sell ASAP? With these seven stocks, all former favorites on both Main Street and Wall Street, consider it high time to take the money and run. 
Via InvestorPlace
Does Ocugen Have a Shot at Winning EUA for Its COVID Vaccine in Kids?
Yes -- but the odds don't look great. 
Via The Motley Fool
Exposures COVID-19
Ocugen, Inc. (OCGN) Q3 2021 Earnings Call Transcript
OCGN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
OCGN Stock Alert: The Earnings News That Has Ocugen Slipping Today
OCGN stock is pulling back after a muted earnings report this morning, as Ocugen makes a big bet on Covaxin for kids. 
Via InvestorPlace
7 Meme Stocks Ready to Regain Their Lost Momentum
Aggressive investors looking to profit off of the recent impressive volatility in certain companies may want to consider these meme stocks. 
Via InvestorPlace
2 Moonshots That Insiders Are Buying… and 3 They’re Not
The first several days of November saw insiders spend nearly $750 million buying up shares of their companies, which is worth your attention. 
Via InvestorPlace
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.